U.S. FDA places hold on Biomea's diabetes trial
06/06/2024 21:20
June 6 (Reuters) - Biomea Fusion BMEA.O said on Thursday the U.S. Food and Drug Administration had placed a clinical hold on its ongoing early-to-mid stage study of its experimental drug for type 1 and 2 diabetes, sending its shares down 55.7% in extended trade. (Reporting by Puyaan Singh in Bengaluru) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes